Novartis accused of owing $47m in IP royalties

15-07-2021

Muireann Bolger

Novartis accused of owing $47m in IP royalties

Novartis should pay a Daiichi Sankyo subsidiary, Plexxikon, $47 million in overdue IP royalties, according to an argument presented before a federal court in California this week.


Plexxikon, Novartis, Tafinlar, BRAF, dabrafenib, compounds

LSIPR